KCI V.A.C.Via User manual

ENGLISHRx Only
NEGATIVE PRESSURE WOUND THERAPY SYSTEM
V.A.C.VIA™ UNTERDRUCKWUNDTHERAPIESYSTEM
V.A.C.VIA™ NEGATIVE PRESSURE WOUNDTHERAPY SYSTEM
V.A.C.VIA™ SYSTÈME DE THÉRAPIE PAR PRESSION NÉGATIVE
V.A.C.VIA™ SISTEMA TERAPEUTICO A PRESSIONE NEGATIVA
V.A.C.VIA™ SISTEMA DE TERAPIA DE PRESIÓN NEGATIVA PARA EL TRATAMIENTO DE HERDAS
V.A.C.VIA™ NEGATIVE PRESSURE WOUNDTHERAPY SYSTEM
V.A.C.VIA™ SÅRBEHANDLINGSSYSTEM MED NEGATIVT TRYCK
V.A.C.VIA™ SISTEMA DE TERAPIA DE LESÕES COM PRESSÃO NEGATIVA
V.A.C.VIA™ NEGATİF BASINÇ YARA TEDAVİ SİSTEMİ
V.A.C.VIA™ ΘΕΡΑΠΕΙΑ ΕΠΟΥΛΣΗΣ ΤΡΑΥΜΑΤΝ ΜΕ ΕΦΑΡΜΟΓΗ ΑΡΝΗΤΙΚΗΣ ΠΙΕΣΗΣ
V.A.C.VIA™ALIPAINEIMUHOITOJÄRJESTELMÄ
V.A.C.VIA™SÅRBEHANDLINGSSYSTEM MED UNDERTRYKK
INSTRUCTIONS FOR USE
GEBRAUCHSANWEISUNG / GEBRUIKSAANWIJZING / MODE D’EMPLOI
ISTRUZIONI PER L’USO / INSTRUCCIONES DE USO / BRUGERVEJLEDNING
BRUKSANVISNING / INSTRUÇÕES DE USO / KULLANIM TALIMATLARI
ΟΗΓΙΕΣ ΧΡΗΣΗΣ / KÄYTTÖOHJEET / BRUKSANVISNING

DISCLAIMER OF WARRANTY AND LIMITATION OF REMEDY
KCI HEREBY DISCLAIMS ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION
ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ON THE
KCI PRODUCT(S) DESCRIBED IN THIS PUBLICATION. ANY WRITTEN WARRANTY OFFERED BY KCI SHALL
BE EXPRESSLY SET FORTH IN THIS PUBLICATION OR INCLUDED WITH THE PRODUCT. UNDER NO
CIRCUMSTANCES SHALL KCI BE LIABLE FOR ANY INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES
AND EXPENSES, INCLUDING DAMAGES OR INJURY TO PERSON OR PROPERTY, DUE IN WHOLE OR IN
PART TO THE USE OF THE PRODUCT OTHER THAN THOSE FOR WHICH DISCLAIMER OF WARRANTY OR
LIMITATION OF LIABILITY IS EXPRESSLY PROHIBITED BY SPECIFIC, APPLICABLE LAW. NO PERSON HAS THE
AUTHORITY TO BIND KCI TO ANY REPRESENTATION OR WARRANTY EXCEPT AS SPECIFICALLY SET FORTH
IN THIS PARAGRAPH.
Descriptions or specifications in KCI printed matter, including this publication, are meant solely to
generally describe the product at the time of manufacture and do not constitute any express warranties
except as set forth in the written limited warranty included with this product. Information in this
publication may be subject to change at any time. Contact KCI for updates.

3
TABLE OF CONTENTS
Warnings and Important Information for Users................................................................................................................................ 4
V.A.C.® Therapy Safety Information............................................................................................................................................................5
Indications for Use...............................................................................................................................................................................................5
Contraindications.................................................................................................................................................................................................6
Warnings....................................................................................................................................................................................................................6
Precautions............................................................................................................................................................................................................... 10
Considerations for Transitioning V.A.C.® Therapy Into Home Care......................................................................................... 12
V.A.C.Via™ Therapy System Application Instructions .....................................................................................................................13
Therapy Unit Components............................................................................................................................................................................. 13
V.A.C.Via™ Therapy System Dressing Components........................................................................................................................13
Wound Preparation............................................................................................................................................................................................. 14
V.A.C.® GranuFoam™ Spiral Dressing Application............................................................................................................................. 16
V.A.C.® GranuFoam™ Spiral Dressing Application for
Incision Management........................................................................................................................................................................................ 17
Incision Site Preparation...................................................................................................................................................................................17
Drain Tubes and Pain Management Control Devices.................................................................................................................... 17
Incision Site Dressing Application..............................................................................................................................................................17
V.A.C.® Advanced Drape Application........................................................................................................................................................ 18
SensaT.R.A.C.® Pad Application..................................................................................................................................................................... 19
V.A.C.Via™ Canister Installation.....................................................................................................................................................................20
Beginning Therapy...............................................................................................................................................................................................21
Unit Troubleshooting......................................................................................................................................................................................... 22
Duration of Therapy............................................................................................................................................................................................23
Therapy Life Indicators......................................................................................................................................................................................23
Dressing Removal.................................................................................................................................................................................................23
Canister Removal and Replacement........................................................................................................................................................ 24
Leaks.............................................................................................................................................................................................................................24
Correcting a Leak Condition.......................................................................................................................................................................... 25
Alarms..........................................................................................................................................................................................................................25
Battery Charging...................................................................................................................................................................................................27
Important Information to Discuss with Patients...............................................................................................................................28
Daily Use.....................................................................................................................................................................................................................28
Device Disposal ..................................................................................................................................................................................................... 28
Explanation of Symbols Used....................................................................................................................................................................... 29
Specifications..........................................................................................................................................................................................................30
Contact Information........................................................................................................................................................................................... 32

4
WARNINGS AND IMPORTANT INFORMATION FOR USERS
In order for KCI products to perform properly, KCI recommends the following conditions. Failure to
comply with these conditions will void any applicable warranties.
• Use this product only in accordance with these instructions and applicable product labeling.
• Assembly, operations, extensions, re-adjustments, modifications, technical maintenance or
repairs must be performed by qualified personnel authorized by KCI.
• Ensure the electrical installation of the room complies with the appropriate national electrical
wiring standards. To avoid the risk of electrical shock, this product must be connected to a
grounded power receptacle.
• Cell phones or similar products could affect the therapy unit. Move the therapy unit away from
these devices if interference is suspected.
• Do not operate this product if it has a damaged power cord, power supply or plug. If these
components are worn or damaged, contact KCI.
• Do not drop or insert any object into any opening or tubing of this product.
• Do not connect this product or its components to devices not recommended by KCI.
• Do not modify the therapy unit or dressing. Do not connect the therapy unit or dressing to
other devices being used.
• Use only V.A.C.® Dressings with this product.
• Keep this product away from heated surfaces.
• Equipment not suitable for use in presence of flammable anesthetic mixture with air, oxygen
or nitrous oxide.
• Avoid spilling fluids on any part of this product.
• Do not make any changes to the settings on the therapy unit without instructions from the
treating physician.
• Small Parts - Choking Hazard
• The V.A.C.Via™ Negative Pressure Wound Therapy System is a medical device, not a toy. Keep
away from children, pets and pests as they can damage the dressing and therapy unit and affect
performance. Keep the therapy unit free of dust and lint as they can also damage the dressing
and therapy unit and affect performance.
WARNING: The V.A.C.Via™ Therapy Unit has no serviceable parts and should not be opened,
disassembled or otherwise modied by the user, and should be replaced as a unit. All
assembly, operations, adjustments, modications, maintenance and repairs must be carried
out by qualied personnel authorized by KCI.
Electric Shock Hazard - Do not open any electrical cover on the therapy unit. There are no serviceable
parts. Refer to qualified KCI service personnel.
Fluids remaining on the electronic controls can cause corrosion that may cause the electronic
components to fail. Component failures may cause the unit to operate erratically, possibly
producing potential hazards to patient and sta. If spills do occur, unplug the unit immediately
and clean with an absorbent cloth. Ensure there is no moisture in or near the power
connection and power supply components before reconnecting power. If the product does not
work properly, contact KCI.

5
The V.A.C.Via™ Therapy System is a single use, disposable therapy system designed to provide V.A.C.®
Therapy for moderate to low severity wounds. The V.A.C.Via™ Therapy System consists of a therapy unit,
charger cord, carrying case and replaceable canister used together with a V.A.C.Via™ Dressing. The therapy
unit has a seven day lifespan and a rechargeable battery. The unit’s control panel allows the user to
select Continuous therapy or Dynamic Pressure Control™ (DPC) Therapy at a negative pressure of either
75 mmHg or 125 mmHg. As a safety feature, all selector buttons need to be pressed and held for three
seconds for operation. V.A.C.Via™ Dressings consist of a V.A.C.® GranuFoam™ Spiral Dressing (either small
or medium), V.A.C.® Advanced Drape and a SensaT.R.A.C.™ Pad. Additional dressings and canisters may be
ordered separately.
V.A.C.® THERAPY SAFETY INFORMATION
Disposable components of the V.A.C.® Therapy System are provided as indicated on the associated
product labeling. V.A.C.® Therapy Unit canisters are packaged sterile or fluid path sterile and are latex-free.
All disposable components of the V.A.C.® Therapy System are for single use only. To help ensure safe and
effective use, the V.A.C.® GranuFoam™ Dressing, V.A.C. GranuFoam Silver® Dressing and V.A.C.® WhiteFoam
Dressings are to be used only with V.A.C.® Therapy Units.
All disposable components of the V.A.C.® Therapy System are for single use only. Re-use of disposable
components may result in wound contamination, infection and / or failure of the wound to heal.
The decision to use clean versus sterile / aseptic technique is dependent upon wound pathophysiology,
physician / clinician preference and institutional protocol.
IMPORTANT: As with any prescription medical device, failure to consult a physician and carefully read
and follow all therapy unit and dressing instructions and safety information prior to each use may lead
to improper product performance and the potential for serious or fatal injury. Do not adjust therapy unit
settings or perform therapy application without directions from / or supervision by the treating physician.
The V.A.C.Via™ Negative Pressure Wound Therapy System is intended to be operated by qualified clinical
caregivers in acute, extended or home care settings. In service and training programs for use of V.A.C.®
Therapy are available. Patients may monitor therapy unit information signals under the direction or
supervision of the clinical caregiver. Patients are not expected to apply or change V.A.C. Via™ Dressings or
adjust therapy unit settings. For further information refer to Considerations for Transitioning V.A.C.®
Therapy into Homecare.
INDICATIONS FOR USE
The V.A.C.Via™ Negative Pressure Wound Therapy System is an integrated wound management system
for use in acute, extended and home care settings.
When used on open wounds, the V.A.C.Via™ Negative Pressure Wound Therapy System is intended to
create an environment that promotes wound healing by secondary or tertiary (delayed primary) intention
by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and
perfusion, and by removing exudate and infectious material. Open wound types include: chronic, acute,
traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure or
venous insufficiency), flaps and grafts.
When used on closed surgical incisions, the V.A.C.Via™ Negative Pressure Wound Therapy System is
intended to manage the environment of surgical incisions that continue to drain following sutured or
stapled closure by maintaining a closed environment and removing exudates via the application of
negative pressure wound therapy.

6
CONTRAINDICATIONS
• Do not place foam dressings of theV.A.C.® Therapy System directly in contact with exposed
blood vessels, anastomotic sites, organs or nerves.
NOTE: Refer to Warnings section for additional information concerning Bleeding.
• V.A.C.® Therapy is contraindicated for patients with:
• Malignancy in the wound
• Untreated osteomyelitis
NOTE: Refer to Warnings section for Osteomyelitis information.
• Non-enteric and unexplored fistulas
• Necrotic tissue with eschar present
NOTE: After debridement of necrotic tissue and complete removal of eschar, V.A.C.® Therapy may be
used.
WARNINGS
Bleeding: With or without using V.A.C.® Therapy, certain patients are at high risk of bleeding
complications. The following types of patients are at increased risk of bleeding, which, if uncontrolled,
could be potentially fatal:
• Patients who have weakened or friable blood vessels or organs in or around the wound as a
result of, but not limited to:
• Suturing of the blood vessel (native anastamoses or grafts) / organ
• Infection
• Trauma
• Radiation
• Patients without adequate wound hemostasis
• Patients who have been administered anticoagulants or platelet aggregation inhibitors
• Patients who do not have adequate tissue coverage over vascular structures
If V.A.C.® Therapy is prescribed for patients who have an increased risk of bleeding
complications, they should be treated and monitored in a care setting deemed
appropriate by the treating physician.
If active bleeding develops suddenly or in large amounts duringV.A.C.® Therapy, or
if frank (bright red) blood is seen in the tubing or in the canister, immediately stop
V.A.C.® Therapy, leave dressing in place, take measures to stop the bleeding and seek
immediate medical assistance.The V.A.C.®Therapy Units and dressings should not be
used to prevent, minimize or stop vascular bleeding.

7
• Protect Vessels and Organs: All exposed or superficial vessels and organs in or around
the wound must be completely covered and protected prior to the administration of V.A.C.®
Therapy.
Always ensure that V.A.C.® Foam Dressings do not come in direct contact with vessels or organs.
Use of a thick layer of natural tissue should provide the most effective protection. If a thick layer
of natural tissue is not available or is not surgically possible, multiple layers of meshed, non-
adherent material or bio-engineered tissue may be considered as an alternative, if deemed by
the treating physician to provide a complete protective barrier. If using non-adherent materials,
ensure they are secured in a manner that will maintain their protective position throughout
therapy.
Consideration should also be given to the negative pressure setting and therapy mode used
when initiating therapy.
Caution should be taken when treating large wounds that may contain hidden vessels which
may not be readily apparent. The patient should be closely monitored for bleeding in a care
setting deemed appropriate by the treating physician.
• Infected Blood Vessels: Infection may erode blood vessels and weaken the vascular wall
which may increase susceptibility to vessel damage through abrasion or manipulation.
Infected blood vessels are at risk of complications, including bleeding, which, if
uncontrolled, could be potentially fatal. Extreme caution should be used when V.A.C.®
Therapy is applied in close proximity to infected or potentially infected blood vessels.
(Refer to Protect Vessels and Organs section above). The patient should be closely monitored
for bleeding in a care setting deemed appropriate by the treating physician.
• Hemostasis, Anticoagulants, and Platelet Aggregation Inhibitors: Patients without
adequate wound hemostasis have an increased risk of bleeding, which, if uncontrolled, could
be potentially fatal. These patients should be treated and monitored in a care setting deemed
appropriate by the treating physician.
Caution should be used in treating patients on doses of anticoagulants or platelet aggregation
inhibitors thought to increase their risk for bleeding (relative to the type and complexity of the
wound). Consideration should be given to the negative pressure setting and therapy mode
used when initiating therapy.
• Hemostatic Agents Applied at the Wound Site: Non-sutured hemostatic agents (for
example, bone wax, absorbable gelatin sponge or spray wound sealant) may, if disrupted,
increase the risk of bleeding, which, if uncontrolled, could be potentially fatal. Protect against
dislodging such agents. Consideration should be given to the negative pressure setting and
therapy mode used when initiating therapy.
• Sharp Edges: Bone fragments or sharp edges could puncture protective barriers, vessels
or organs, causing injury. Any injury could cause bleeding, which, if uncontrolled, could be
potentially fatal. Beware of possible shifting in the relative position of tissues, vessels or organs
within the wound that might increase the possibility of contact with sharp edges. Sharp edges
or bone fragments must be covered or eliminated from the wound area, to prevent them from
puncturing blood vessels or organs before the application of V.A.C.® Therapy. Where possible,
completely smooth and cover any residual edges to decrease the risk of serious or fatal injury,
should shifting of structures occur. Use caution when removing dressing components from the
wound so that wound tissue is not damaged by unprotected sharp edges.

8
Infected Wounds: Infected wounds should be monitored closely and may require more frequent
dressing changes than non-infected wounds, dependent upon factors such as wound conditions,
treatment goals and instillation therapy parameters (for the V.A.C. Instill® Therapy System). Refer to
dressing application instructions (found in V.A.C.® Dressing cartons) for details regarding dressing change
frequency. As with any wound treatment, clinicians and patients / caregivers should frequently monitor
the patient’s wound, periwound tissue and exudate for signs of infection, worsening infection or other
complications. Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased
warmth in the wound or periwound area, purulent discharge or strong odor. Infection can be serious,
and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and / or
fatal injury. Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache,
dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever,
refractory and / or orthostatic hypotension or erythroderma (a sunburn-like rash). If there are any signs
of the onset of systemic infection or advancing infection at the wound site, contact the treating
physician immediately to determine if V.A.C.® Therapy should be discontinued. For wound
infections relating to blood vessels, please also refer to the section titled Infected Blood Vessels.
Osteomyelitis: V.A.C.® Therapy should NOT be initiated on a wound with untreated osteomyelitis.
Consideration should be given to thorough debridement of all necrotic, non-viable tissue, including
infected bone (if necessary) and appropriate antibiotic therapy. Protect intact bone with a single layer of
non-adherent material.
Protect Tendons, Ligaments and Nerves: Tendons, ligaments and nerves should be protected to
avoid direct contact with V.A.C.® Foam Dressings. These structures may be covered with natural tissue,
meshed non-adherent material or bio-engineered tissue to help minimize risk of desiccation or injury.
Foam Placement: Always use V.A.C.® Dressings from sterile packages that have not been opened
or damaged. Do not place any foam dressing into blind / unexplored tunnels. The V.A.C.® WhiteFoam
Dressing may be more appropriate for use with explored tunnels. Do not force foam dressings into any
area of the wound, as this may damage tissue, alter the delivery of negative pressure or hinder exudate
and foam removal. Always count the total number of pieces of foam used in the wound. Document the
foam quantity and dressing change date on the drape or Foam Quantity Label if available, and in the
patient’s chart.
V.A.C.® Foam Dressings are radiolucent, not detectable on X-Ray.
Foam Removal: V.A.C.® Foam Dressings are not bioabsorbable. Always count the total number of pieces
of foam removed from the wound and ensure the same number of foam pieces are removed as were
placed. Foam left in the wound for greater than the recommended time period may foster ingrowth
of tissue into the foam, create difficulty in removing foam from the wound or lead to infection or other
adverse events. If dressing adheres to wound consider introducing sterile water or normal saline into
the dressing, waiting 15 - 30 minutes, then gently removing the dressing from the wound. Regardless
of treatment modality, disruption of the new granulation tissue during any dressing change may result
in bleeding at the wound site. Minor bleeding may be observed and considered expected. However,
patients with increased risk of bleeding, as described in the Bleeding section, have a potential for more
serious bleeding from the wound site. As a precautionary step, consider using V.A.C.® WhiteFoam or
non-adherent material underneath the V.A.C.® GranuFoam™ Dressing to help minimize the potential for
bleeding at dressing removal in these patients. If significant bleeding develops, immediately discontinue
the use of the V.A.C.® Therapy System, take measures to stop the bleeding, and do not remove the
foam dressing until the treating physician or surgeon is consulted. Do not resume the use of the V.A.C.®
Therapy System until adequate hemostasis has been achieved and the patient is not at risk for continued
bleeding.

9
Keep V.A.C.® Therapy On: Never leave a V.A.C.® Dressing in place without active V.A.C.® Therapy for more
than two hours. If therapy is off for more than two hours, remove the old dressing and irrigate the wound.
Either apply a new V.A.C.® Dressing from an unopened sterile package and restart V.A.C.® Therapy, or apply
an alternative dressing at the direction of the treating physician.
Acrylic Adhesive: The V.A.C.® Advanced Drape has an acrylic adhesive coating, which may present a
risk of an adverse reaction in patients who are allergic or hypersensitive to acrylic adhesives. If a patient
has a known allergy or hypersensitivity to such adhesives, do not use the V.A.C.® Therapy System. If any
signs of allergic reaction or hypersensitivity develop, such as redness, swelling, rash, urticaria or significant
pruritus, discontinue use and consult a physician immediately. If bronchospasm or more serious signs of
allergic reaction appear, seek immediate medical assistance.
Debrillation: Remove the V.A.C.® Dressing if defibrillation is required in the area of dressing placement.
Failure to remove the dressing may inhibit transmission of electrical energy and / or patient resuscitation.
Magnetic Resonance Imaging (MRI) - V.A.C.®Therapy Unit: The V.A.C.® Therapy Unit is MR unsafe. Do
not take the V.A.C.® Therapy Unit into the MR environment.
Magnetic Resonance Imaging (MRI) - V.A.C.® Dressings: V.A.C.® Dressings can typically remain on the
patient with minimal risk in an MR environment, assuming that use of the V.A.C.® Therapy System is not
interrupted for more than two hours (refer to Keep V.A.C.® Therapy On section).
Hyperbaric Oxygen Therapy (HBO): Do not take the V.A.C.® Therapy Unit into a hyperbaric oxygen
chamber. The V.A.C.® Therapy Unit is not designed for this environment and should be considered a fire
hazard. After disconnecting the V.A.C.® Therapy Unit, either (i) replace the V.A.C.® Dressing with another
HBO compatible material during the hyperbaric treatment or (ii) cover the unclamped end of the V.A.C.®
Tubing with dry gauze. For HBO therapy, the V.A.C.® Tubing must not be clamped. Never leave a V.A.C.®
Dressing in place without active V.A.C.® Therapy for more than two hours (refer to Keep V.A.C.® Therapy
On section).

10
PRECAUTIONS
Standard Precautions: To reduce the risk of transmission of bloodborne pathogens, apply standard
precautions for infection control with all patients, per institutional protocol, regardless of their diagnosis
or presumed infection status. In addition to gloves, use gown and goggles if exposure to body fluids is
likely.
Closed Surgical Incisions: For maximum benefit the V.A.C.® Therapy System should be applied
immediately post surgery to clean surgically closed wounds. It is to be continuously applied for a
minimum of two days up to a maximum of seven days. The ActiV.A.C.®, InfoV.A.C.®, V.A.C. ATS®, V.A.C.
Freedom®, V.A.C.Via™ and V.A.C.® Simplicity™ Therapy Systems can transition home with the patient;
however, all dressing changes should be performed under direct medical supervision.
The V.A.C.® Therapy System will not be effective in addressing complications associated with
the following:
• Ischemia to the incision or incision area
• Untreated or inadequately treated infection
• Inadequate hemostasis of the incision
• Cellulitis of the incision area
Continuous versus DPCV.A.C.® Therapy: Continuous, rather than DPC V.A.C.® Therapy is
recommended over unstable structures, such as an unstable chest wall or non-intact fascia, in order
to help minimize movement and stabilize the wound bed. Continuous therapy is also generally
recommended for patients at increased risk of bleeding, highly exudating wounds, fresh flaps and grafts
and wounds with acute enteric fistulae.
Patient Size andWeight: The size and weight of the patient should be considered when prescribing
V.A.C.® Therapy. Infants, children, certain small adults and elderly patients should be closely monitored
for fluid loss and dehydration. Also, patients with highly exudating wounds or large wounds in relation to
the patient size and weight should be closely monitored, as these patients have a risk of excessive fluid
loss and dehydration. When monitoring fluid output, consider the volume of fluid in both the tubing and
canister.
Spinal Cord Injury: In the event a patient experiences autonomic dysreflexia (sudden changes in blood
pressure or heart rate in response to stimulation of the sympathetic nervous system), discontinue V.A.C.®
Therapy to help minimize sensory stimulation and seek immediate medical assistance.
Bradycardia: To minimize the risk of bradycardia, V.A.C.® Therapy must not be placed in proximity to the
vagus nerve.
Enteric Fistulas: Wounds with enteric fistulas require special precautions to optimize V.A.C.® Therapy.
V.A.C.® Therapy is not recommended if enteric fistula effluent management or containment is the sole
goal of therapy.

11
Protect Periwound Skin: Consider use of a skin preparation product to protect periwound skin. Do
not allow foam to overlap onto intact skin. Protect fragile / friable periwound skin with additional V.A.C.®
Advanced Drape, hydrocolloid or other transparent film.
• Multiple layers of V.A.C.® Advanced Drape may decrease the moisture vapor transmission rate,
which may increase the risk of maceration.
• If any signs of irritation or sensitivity to the drape, foam, or tubing assembly appear, discontinue
use and consult a physician.
• To avoid trauma to the periwound skin, do not pull or stretch the drape over the foam dressing
during drape application.
• Extra caution should be used for patients with neuropathic etiologies or circulatory
compromise.
Circumferential Dressing Application: Avoid use of circumferential dressings except in the presence
of anasarca or excessively weeping extremities, where a circumferential drape technique may be
necessary to establish and maintain a seal. Consider using multiple small pieces of V.A.C.® Advanced
Drape rather than one continuous piece to minimize the risk of decreased distal circulation. Extreme care
should be taken not to stretch or pull the drape when securing it, but let it attach loosely and stabilize
the edges with an elastic wrap, if necessary. When using circumferential drape applications, it is crucial
to systematically and recurrently palpate distal pulses and assess distal circulatory status. If circulatory
compromise is suspected, discontinue therapy, remove dressing, and contact a treating physician.
V.A.C.® Therapy Unit Pressure Excursions: In rare instances, tubing blockages with the V.A.C.® Therapy
Unit may result in brief vacuum excursions to more than 250 mmHg negative pressure. Resolve alarm
conditions immediately. Refer to the Alarms section of these instructions for use or contact your KCI
representative for additional information.

12
CONSIDERATIONS FOR TRANSITIONING V.A.C.® THERAPY INTO HOME
CARE
WARNING: Patients with an increased risk of bleeding complications should be treated and
monitored in a care setting deemed appropriate by the treating physician.
In addition to the contraindications, warnings and precautions for use of V.A.C.® Therapy, consider the
following before prescribing V.A.C.® Therapy for use in the home care setting.
• The Patient’s Situation:
• Clinical condition (adequate hemostasis and a low risk of active and / or large amounts of
bleeding at the wound site)
• Home environment (patient or family member / caregiver able to read and understand
safety labeling, able to respond to alarms, able to follow instructions for use)
• The Patient’s Wound:
• Must be assessed for exposed vessels, anastomotic sites, organs, and nerves. Adequate
protection must be present without the need for a protective, non-adherent layer placed
between the V.A.C.® Dressing and the exposed structure for the sole purpose of protection
of these structures (refer to Protect Vessels and Organs in the Warnings section).
• Labeling:
• The prescribing physician and health care clinician should be familiar with the V.A.C.®
Therapy instructional materials that accompany the therapy unit and dressing cartons into
the home. The prescribing physician and / or healthcare clinician should carefully review
these materials with the patient and patient’s caregiver.
• KCI offers in service and training programs for use of V.A.C.® Therapy. Contact your local KCI
representative. In the U.S., call 1-800-275-4524 for scheduling.
If there are any questions regarding the proper placement or usage of V.A.C.® Therapy, please refer to the
V.A.C.® Therapy Clinical Guidelines for more detailed instructions or contact your local KCI representative.
For additional and most current information, please see KCI’s website at www.kci1.com or www.kci-
medical.com.

13
V.A.C.VIA™ THERAPY SYSTEM APPLICATION INSTRUCTIONS
THERAPY UNIT COMPONENTS
The V.A.C.Via™ Therapy System contains the following single use, disposable components:
V.A.C.VIA™THERAPY SYSTEM DRESSING COMPONENTS
Wounds being treated with the V.A.C.Via™ Therapy System should be monitored on a regular basis. In a
monitored, non-infected wound, V.A.C.Via™ Dressings should be changed every 48 to 72 hours, but no
less than three times per week, with frequency adjusted by the clinician as appropriate. Infected wounds
must be monitored often and very closely. For these wounds, dressings may need to be changed more
often than 48 to 72 hours; the dressing change intervals should be based on a continuing evaluation of
wound condition and the patient’s clinical presentation, rather than a fixed schedule.
For more information refer to the V.A.C.® Therapy Clinical Guidelines available at www.kci1.com, www.
kci-medical.com, vactherapy.com or contact your local KCI representative for a printed copy.
~250
~200
~150
~100
~50
V.A.C.Via™ Therapy
Unit
V.A.C.Via™ Therapy
Unit Carry Case V.A.C.Via™ Power Supply
with Power Cord
V.A.C.Via™ Therapy
Unit Canister
V.A.C.® GranuFoam™ Spiral
Dressing - Medium
(Quantity: 2)
V.A.C.® GranuFoam™ Spiral
Dressing - Small
(Quantity: 2)
V.A.C.® Ruler
V.A.C.® Advanced Drape
(Quantity with Small: 2
Quantity with Medium: 3)
3M™ Cavilon™ No Sting
Barrier Film
(Quantity with Small: 1
Quantity with Medium: 2
SensaT.R.A.C.™ Pad

14
WOUND PREPARATION
WARNING: Review all V.A.C.® Safety Information before beginning wound preparation.
1. Remove and discard previous dressing per institution protocol. Thoroughly inspect wound to
ensure all pieces of dressing components have been removed. Refer to Warnings, Foam Removal
section.
NOTE: If dressing adheres to wound, consider introducing sterile water or normal saline into the dressing,
waiting 15-30 minutes, then gently removing the dressing from the wound. Consider placing a non-
adherent material prior to application of subsequent V.A.C.Via™ Dressings.
If patient complains of or exhibits signs of discomfort during the dressing change, consider use of a
non-adherent material prior to subsequent foam dressing placement, pre-medication, or introduction of
a topical anesthetic agent into the dressing as prescribed by physician 15 - 20 minutes prior to dressing
removal. Refer to V.A.C.® Therapy Clinical Guidelines for specific recommendations.
2. Ensure debridement of all necrotic, non-viable tissue, including bone, eschar, or hardened slough, as
prescribed by physician.
3. Perform thorough wound and periwound area cleaning per physician order or institution protocol
prior to each dressing application.
4. Protect fragile / friable periwound skin with additional V.A.C.® Advanced Drape or other similar
medical grade transparent film, skin protectant or hydrocolloid. Do not allow foam to overlap onto
intact skin.
NOTE: Depending on region, 3M™ Cavilon™ No Sting Barrier Film may be provided in the dressing
package.
Application of the 3M™ Cavilon™ No Sting Barrier Film (if used):
Additional product information for the 3M™ Cavilon™ No Sting Barrier Film may be obtained by calling
3M™ at 1-888-3M HELPS (1-888-364-3577) or by referring to the 3M™ website at www.3m.com for the
3M™ Cavilon™ No Sting Barrier Film, product ID, 70200763921. 3M™ is located at 3M™ Center, St. Paul, MN
55144-1000.
a. Skin should be clean and dry prior to application of 3M™ Cavilon™ No Sting Barrier Film.
b. Use supplied wipe to apply a uniform coating of film over the desired area (Fig. 1).
c. If an area is missed, reapply to that area only after first application of 3M™ Cavilon™ No Sting
Barrier Film has dried (approximately 30 seconds).
Fig. 1

15
d. If 3M™ Cavilon™ No Sting Barrier Film is applied to area with skin folds or other skin-to-skin
contact, make sure that skin-contact areas are separated to allow the film to thoroughly dry
before returning to normal position.
• Allow 3M™ Cavilon™ No Sting Barrier Film to thoroughly dry before covering with
dressings.
• Reapplication of 3M™ Cavilon™ No Sting Barrier Film is necessary each time
dressings are changed; the barrier film is removed by the V.A.C.® Advanced Drape
adhesive.
e. If desired, the film can be removed by using most medical adhesive removers as directed.
Clean and dry the involved area and reapply 3M™ Cavilon™ No Sting Barrier Film.
5. Ensure adequate hemostasis has been achieved (refer to Warnings, Bleeding section,
Hemostasis, Anticoagulants and Platelet Aggregation Inhibitors).
6. Protect sensitive structures, vessels and organs (refer to Warnings, Bleeding section, Protect
Vessels and Organs).
7. Sharp edges or bone fragments must be eliminated from wound area or covered (refer to
Warnings, Bleeding section, Sharp Edges).

16
V.A.C.® GRANUFOAM™ SPIRAL DRESSING APPLICATION
Refer to V.A.C.® Therapy Clinical Guidelines for detailed instructions for treating different wound types and
for multiple wound applications.
1. Assess wound dimensions and pathology, including the presence of undermining or tunnels (Fig.
2). Use V.A.C.® WhiteFoam Dressing with explored tunnels. Do not place any foam dressing into
blind / unexplored tunnels. V.A.C.® Dressings may be used for wounds with shallow undermining or
tunnel areas where the distal aspect is visible.
NOTE: If adjunct materials are utilized under the V.A.C.® Dressing, they must be meshed or fenestrated to
allow for effective delivery of negative pressure and exudate removal.
2. Carefully tear the V.A.C.® GranuFoam™ Spiral Dressing along the perforation to a size that will allow
the foam to be placed gently into the wound without overlaping intact skin (Fig. 3).
CAUTION: Do not cut or tear the foam over the wound, as fragments may fall into the wound (Fig. 4).
Away from wound site, rub foam edges to remove any fragments or loose particles that may fall into or
be left in the wound.
3. Gently place foam into wound cavity, ensuring contact with all wound surfaces (Fig. 5). Do not
force the V.A.C.® GranuFoam™ Spiral Dressing into any areas of the wound.
NOTE: Ensure foam-to-foam contact between adjacent pieces of foam for even distribution of negative
pressure.
NOTE: Always note the total number of pieces of foam used in the wound and document on the
supplied foam quantity label (attached to the SensaT.R.A.C. ™ pad tubing) and in the patient’s chart.
NOTE: Superficial or retention sutures should be covered with a single layer of non-adherent material
placed between the sutures and the V.A.C.® Advanced Drape.
Fig. 2
Fig. 4
Fig. 3
Fig. 5

17
V.A.C.® GRANUFOAM™ SPIRAL DRESSING APPLICATION FOR
INCISION MANAGEMENT
INCISION SITE PREPARATION
1. Prior to surgery, shave or clip the surgical area per institution protocol where the dressing will be
applied to improve dressing adhesion and seal integrity.
2. Immediately post surgery, clean the application site per physician’s orders.
3. Pat the application site dry with sterile gauze. To ensure proper adhesion, the application site must
be completely dry before dressing is applied.
DRAIN TUBES AND PAIN MANAGEMENT CONTROL DEVICES
The V.A.C.® Therapy System dressings can be used with both drain tubes and pain devices, provided the
dressing is not placed over tubing where it exits the skin. Surgical drains must be routed under the skin
beyond the boundary of the dressing and function independently of the V.A.C.® Therapy System.
NOTE: While the concomitant use of surgical drains is allowable with the V.A.C.® Therapy System, the
system must not be used as an outlet or reservoir for the drain.
INCISION SITE DRESSING APPLICATION
1. Clean skin around incision, per institution protocol or physician’s orders.
2. Apply skin protectant / skin adhesive to area around the incision and approximately 5.1 cm on
either side to assist with dressing seal integrity
3. Protect intact skin on both sides of the suture line with V.A.C. ® Advanced Drape, hydrocolloid or
other transparent film (‘picture frame’ the suture or staple line), leaving the suture line exposed.
4. Place a non-adherent layer (i.e. oil emulsion, petroleum or silicone dressing) over length of incision.
Include at least 2.5 cm over each end of the incision.
5. Cut V.A.C.® GranuFoam™ Spiral Dressing long enough to cover entire incision and at least 2.5 cm
over either end.
6. Place V.A.C.® GranuFoam™ Spiral Dressing strips onto entire length of non adherent layer. If multiple
strips are used, ensure that the strips touch each other so that negative pressure is applied over the
length of the incision. Do not allow V.A.C.® GranuFoam™ Spiral Dressing to touch intact skin.
7. Cut V.A.C.® Advanced Drape to allow for coverage of the V.A.C.® GranuFoam™ Spiral Dressing and
3 - 5 cm contact with intact skin. An additional strip of drape can be used and overlapped at the
edges to form a seal.
8. Place V.A.C® Advanced Drape gently over the top of the V.A.C.® GranuFoam™ Spiral Dressing and
then down the sides, extending onto intact skin. Refer V.A.C.® Advanced Drape Application
section.
NOTE: To avoid trauma to the periwound skin, do not pull or stretch the drape over the foam during
drape application.
9. Apply SensaT.R.A.C.™ Pad as described in the SensaT.R.A.C.™ Pad Application section.
10. Activate V.A.C.® Therapy at -125 mmHg Continuous.

18
V.A.C.® ADVANCED DRAPE APPLICATION
CAUTION: Patient’s skin condition should be carefully monitored (refer to Precautions, Protect Periwound
Skin section.
1. Trim the V.A.C.® Advanced Drape to cover the V.A.C.® GranuFoam™ Spiral Dressing and an additional
3 - 5 cm border of intact periwound tissue (Fig. 6). The V.A.C.® Advanced Drape may be cut into
multiple pieces for easier handling. Excess V.A.C.® Advanced Drape may be kept to seal difficult
areas, if needed.
2. Carefully remove layer 1 to expose adhesive (Fig. 7). The V.A.C.® Advanced Drape should be held by
the ruler / handling bars.
3. Place the adhesive side down over foam and apply V.A.C.® Advanced Drape to cover foam and intact
skin, ensuring V.A.C.® Advanced Drape covers at least a 3 - 5 cm border of intact periwound tissue.
Smooth any wrinkles in drape to prevent leaks.
4. Remove layer 2 and handling bars and pat V.A.C.® Advanced Drape to ensure an occlusive seal (Fig.
8).
Fig. 6
Fig. 7
Fig. 8

19
SENSAT.R.A.C.® PAD APPLICATION
NOTE: Do not cut off the pad or insert the tubing into the foam dressing. This may occlude the tubing and
cause the V.A.C.® Therapy Unit to alarm.
1. Choose pad application site. Give particular consideration to fluid flow and tubing positioning to
allow for optimal flow, and avoid placement over bony prominences or within creases in the tissue.
2. Pinch V.A.C.® Advanced Drape and carefully cut an approximately 2.5 cm hole through the V.A.C.®
Advanced Drape (Fig. 9). The hole should be large enough to allow for removal of fluid and / or
exudate. It is not necessary to cut into the foam.
NOTE: Cut a hole rather than a slit, as a slit may self-seal during therapy.
3. Apply pad, which has a central disc and a surrounding outer adhesive skirt.
a. Remove both backing layers 1 and 2 to expose adhesive (Fig. 10).
b. Place pad opening in central disc directly over hole in V.A.C.® Advanced Drape (Fig. 11).
c. Apply gentle pressure on the central disc and outer skirt to ensure complete adhesion of the
pad.
d. Pull back on blue tab to remove pad stabilization layer (Fig. 12).
e. If canister is on therapy unit connect dressing tubing to canister. If canister is not on therapy
unit, see V.A.C.Via™ Canister Installation section.
NOTE: To prevent periwound maceration and skin irritation with wounds that are smaller than the
central disc of the pad, it is very important to frame the wound with drape to protect intact skin from
direct foam contact and that the central disc lay on top of a piece of foam at least 6.35 cm in diameter.
It may be necessary to augment the V.A.C.® Dressing with the larger end of the V.A.C.® GranuFoam™
Spiral Dressing. For additional dressing application techniques, refer to the V.A.C.® Therapy Clinical
Guidelines available at www.kci1.com, www.kci-medical.com, vactherapy.com or contact your local KCI
representative for a printed copy.
1
222
1
1
1
1
1
1
2
2.5
cm
Fig. 9 Fig. 10
Fig.
12
Fig.
11

20
V.A.C.VIA™ CANISTER INSTALLATION
The canister used with the V.A.C.Via™ Therapy Unit is a single-use, latex free, sterile, 250 cc / mL container
with graduated markings of approximately 50 cc / mL increments.
NOTE: If the canister is not fully engaged, the V.A.C.Via™ Therapy Unit will alarm.
NOTE: Only use the recommended V.A.C.Via™ Therapy Unit Canister with this product
NOTE: Never reuse a canister.
1. Remove the canister from the sterile package.
2. Hold therapy unit and canister, vertically or horizontally, one in each hand, and slide bottom of
canister into slot on bottom of therapy unit (Fig. 13).
3. Close canister against therapy unit (Fig. 13). The upper locking tab will click when canister is
secured (Fig. 13).
4. Connect interface pad tubing to canister by aligning and plugging
connector at end of tubing onto tubing ports on side of canister (Fig. 14).
Push together firmly. Ensure clamp on tube is open. Position clamp away
from patient.
Canister
Therapy
Unit
Locking
Tab Tubing Ports / Caps
Fig. 13
Fig. 14